Real world outcomes using novel agents for AML in the UK
Research type
Research Study
Full title
Real world outcomes using novel agents for acute myeloid leukaemia in the United Kingdom
IRAS ID
305432
Contact name
Richard Dillon
Contact email
Sponsor organisation
Guy's & St Thomas' Foundation NHS Trust
Duration of Study in the UK
1 years, 7 months, 1 days
Research summary
Acute myeloid leukaemia (AML) is a blood cancer which in fit young adults is typically treated with intensive chemotherapy. While this is potentially curative, it is associated with significant side effects and the requirement for long hospital admissions. Infection is a major issue during AML treatment, as both the disease and the chemotherapy impair the immune system. \n\nEarly data suggested that COVID-19 is associated with a very high rate of death in AML patients undergoing intensive chemotherapy. Because of this, and the need for significant hospital resources to deliver intensive chemotherapy, the NHS made available two new, less intensive, targeted therapies for the treatment of AML during the COVID-19 pandemic - venetoclax and gilteritinib. The aim was to reduce mortality and healthcare resource use.\n\nMany hundreds of patients across the UK have been treated with these two medications on the temporary access scheme. The research aims to collect de-identified data from treating patients to describe the outcomes of patients treated with these approaches, both in terms of the safety and effectiveness.
REC name
South West - Central Bristol Research Ethics Committee
REC reference
22/SW/0042
Date of REC Opinion
9 Mar 2022
REC opinion
Favourable Opinion